This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
5 May 2011

Sun Pharma Announces USFDA Approval for Docefrez for Injection

Sun Pharmaceutical announced that USFDA has granted its subsidiary an approval for its New Drug Application (NDA) for DOCEFREZTM (docetaxel) for Injection.

Sun Pharmaceutical Industries Ltd., an international, integrated, speciality pharmaceutical company headquartered in India, announced that USFDA has granted its subsidiary an approval for its New Drug Application (NDA) for DOCEFREZTM (docetaxel) for Injection, 20 mg/vial and 80 mg/vial.

 

This NDA provides for the use of DOCEFREZTM (docetaxel) for Injection, 20 mg/vial and 80 mg/vial for locally advanced or metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and hormone refractory metastatic prostate cancer.

Related News